Jianfeng Xu, MD, DrPHis a genomic translational researcher. He was trained in medicine, public health, and genetic epidemiology from Shanghai Medical University in China and the Johns Hopkins University School of Public Health in the U.S. Dr. Xu’s primary research interests are 1) discovery of genes that are associated with development and progression of diseases, and 2) translation of genomic findings for targeted prevention, screening, and treatment of diseases. He and his colleagues discovered multiple genes for cancer and other diseases and published over 430 papers in high impact journals including New England Journal of Medicine, Nature Genetics, JAMA, Lancet, and Science.
Dr. Xu developed a genetic risk score (GRS) to measure the cumulative effect of multiple risk-associated variants on disease risk. Since published the GRS method and its application in prostate cancer 10 years ago, he has been working continuously and persistently to improve the GRS method and implement it in clinic.
Continuing Medical Education Credit
Continuing Medical Education (CME) credit is being offered for 2019 - 2020 Genetics and Genomics Grand Rounds series through the University of Arizona College of Medicine - Tucson.
The University of Arizona College of Medicine – Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Arizona College of Medicine – Tucson designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
2019 - 2020 Genetics and Genomics Grand Rounds Learning Objectives
- Integrate advances in genetic diagnosis and treatment into the day-to-day practices of research and clinical care.
- Order appropriate diagnostic evaluations for patients with hereditary medical conditions.
All Faculty, CME Planning Committee Members, and the CME Office Reviewers have disclosed that they do not have any relevant financial relationships with commercial interests that would constitute a conflict of interest concerning this CME activity.